<rst>
<header>
	<relations>
			<rel name="elaboration" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="antithesis" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">4. Discussion</segment>
<segment id="2" parent="1003" relname="attribution">This study examined</segment>
<segment id="3" parent="1003" relname="span">whether the combined administration of 6.0 g of glycine and 0.4 g of tryptophan suppressed the elevation in serum uric acid levels</segment>
<segment id="4" parent="3" relname="elaboration">induced by purine ingestion and increased urinary uric acid excretion .</segment>
<segment id="5" parent="1007" relname="span">The amino acid doses</segment>
<segment id="6" parent="5" relname="elaboration">used for single ingestion</segment>
<segment id="7" parent="1006" relname="same_unit">were based on those</segment>
<segment id="8" parent="1006" relname="elaboration">used in continual supplementation .</segment>
<segment id="9" parent="1009" relname="span">Both glycine and tryptophan are present in dietary proteins</segment>
<segment id="10" parent="9" relname="elaboration">that are ingested in normal daily living .</segment>
<segment id="11" parent="1011" relname="span">However , glycine at doses of up to 90 g per day</segment>
<segment id="12" parent="11" relname="elaboration">administered over several weeks were reported no serious adverse effects .</segment>
<segment id="13" parent="1010" relname="joint">The oral administration of up to 5.0 g of l-tryptophan per day did not lead to any adverse effects in young adult females .</segment>
<segment id="14" parent="1010" relname="joint">Therefore , no adverse effects were attributed to the combined administration of glycine and tryptophan in the current trial .</segment>
<segment id="15" parent="1015" relname="preparation">This study confirmed the safety of combined glycine and tryptophan supplementation .</segment>
<segment id="16" parent="1017" relname="attribution">The current study demonstrated</segment>
<segment id="17" parent="1017" relname="span">that the combined administration of glycine and tryptophan significantly suppressed the elevation in the serum uric acid levels</segment>
<segment id="18" parent="17" relname="elaboration">caused by purine ingestion in healthy subjects .</segment>
<segment id="19" parent="1019" relname="span">The effect of the combined amino acid administration was stronger than that of the same glycine dose alone ,</segment>
<segment id="20" parent="1020" relname="span">indicating that a small amount of tryptophan provides an additional benefit to glycine alone</segment>
<segment id="21" parent="1021" relname="span">in reducing the elevation in the serum uric acid levels</segment>
<segment id="22" parent="21" relname="circumstance">after the ingestion of dietary purines .</segment>
<segment id="23" parent="1023" relname="span">In agreement with previous reports ,</segment>
<segment id="24" parent="23" relname="elaboration">glycine increased urinary uric acid excretion and enhanced urate clearance in the current study .</segment>
<segment id="25" parent="26" relname="attribution">The authors previously reported</segment>
<segment id="26" parent="1025" relname="span">that continual supplementation with glycine and tryptophan led to an increase in urinary pH .</segment>
<segment id="27" parent="1027" relname="joint">Glycine exhibits a buffering action</segment>
<segment id="28" parent="1027" relname="joint">and it is often used as an antacid .</segment>
<segment id="29" parent="1029" relname="joint">The water solubility of uric acid increases with increasing pH levels</segment>
<segment id="30" parent="1029" relname="joint">and uric acid excretion is more favorable in alkaline urine than in acidic urine .</segment>
<segment id="31" parent="1032" relname="span">Therefore , it is possible that the elevation in urinary pH</segment>
<segment id="32" parent="31" relname="elaboration">caused by glycine and tryptophan supplementation enhanced the solubility of urinary uric acid ,</segment>
<segment id="33" parent="1032" relname="elaboration">thereby elevating urinary uric acid excretion and urate clearance .</segment>
<segment id="34" parent="1033" relname="joint">Previous studies provide physiological , physicochemical and clinical validation for the use of citrate salt in the treatment of some types of lithiasis .</segment>
<segment id="35" parent="1035" relname="contrast">Citrate salts treatment substantially increased urinary pH in patients with uric acid lithiasis ,</segment>
<segment id="36" parent="1035" relname="contrast">however , there was no significant change in the amount of urinary uric acid .</segment>
<segment id="37" parent="1036" relname="joint">The mixture of amino acids might be superior to citrate salts in the prevention or treatment of hyperuricemia .</segment>
<segment id="38" parent="1038" relname="same_unit">Herein ,</segment>
<segment id="39" parent="1040" relname="span">although the elevation of urinary pH</segment>
<segment id="40" parent="1041" relname="span">induced by the ingestion of glycine alone was not significant</segment>
<segment id="41" parent="40" relname="elaboration">compared with the effects of placebo ,</segment>
<segment id="42" parent="1042" relname="span">glycine administration enhanced uric acid excretion and urate clearance ,</segment>
<segment id="43" parent="42" relname="elaboration">raising the possibility of other mechanisms .</segment>
<segment id="44" parent="1045" relname="span">Urate transporter 1</segment>
<segment id="45" parent="44" relname="elaboration">( URAT1 ) ,</segment>
<segment id="46" parent="1047" relname="span">a primary reabsorptive urate transporter</segment>
<segment id="47" parent="46" relname="elaboration">that is targeted by pyrazinamide ,</segment>
<segment id="48" parent="1046" relname="same_unit">reportedly disables glycine-induced uricosuria .</segment>
<segment id="49" parent="1049" relname="span">Pyrazinamide may reflect the enhanced urate reabsorption</segment>
<segment id="50" parent="49" relname="elaboration">following the exchange of its active metabolite .</segment>
<segment id="51" parent="1051" relname="span">Thus , glycine may inhibit the reabsorptive action of uric acid ,</segment>
<segment id="52" parent="51" relname="elaboration">which is induced by URAT1 .</segment>
<segment id="53" parent="1053" relname="span">Further studies are needed</segment>
<segment id="54" parent="53" relname="purpose">to elucidate the action of glycine on URAT1 .</segment>
<segment id="55" parent="1054" relname="joint">In the current study , the supplementation with tryptophan alone had no influence on urinary pH , urinary uric acid excretion or urate clearance .</segment>
<segment id="56" parent="1056" relname="preparation">As the effect of tryptophan on URAT1 might be structurally difficult ,</segment>
<segment id="57" parent="1056" relname="joint">tryptophan might have exerted an indirect action against uric acid elevation via its influence on the action of glycine .</segment>
<segment id="58" parent="1058" relname="preparation">Specifically , tryptophan might promote the direct action of glycine against uric acid elevation .</segment>
<segment id="59" parent="1059" relname="span">The maximum serum levels of glycine and tryptophan are achieved within an hour of ingestion ,</segment>
<segment id="60" parent="1060" relname="span">which is followed by rapid decreases</segment>
<segment id="61" parent="60" relname="circumstance">as the amino acids are metabolized .</segment>
<segment id="62" parent="1062" relname="span">Glycine metabolizes various end-products ,</segment>
<segment id="63" parent="62" relname="elaboration">namely glutathione , nucleic acid bases , heme , creatine and bile acids .</segment>
<segment id="64" parent="1064" relname="span">The increases in urinary creatinine excretion and creatinine clearance</segment>
<segment id="65" parent="66" relname="attribution">following the glycine challenge suggest</segment>
<segment id="66" parent="1065" relname="span">that glycine might be partially absorbed back and metabolized to creatinine through creatine .</segment>
<segment id="67" parent="1067" relname="span">Conversely , these urinary parameters did not change in response to the simultaneous supplementation with glycine and tryptophan ,</segment>
<segment id="68" parent="67" relname="elaboration">suggesting the suppression of the conversion of glycine to creatinine by tryptophan .</segment>
<segment id="69" parent="1069" relname="span">In fact , the increases in the serum glycine/creatinine ratio and urinary glycine excretion were more pronounced in response to supplementation with glycine and tryptophan</segment>
<segment id="70" parent="69" relname="antithesis">than with glycine alone .</segment>
<segment id="71" parent="1071" relname="span">Further studies are required</segment>
<segment id="72" parent="1072" relname="span">to clarify the mechanism</segment>
<segment id="73" parent="72" relname="elaboration">underlying the contribution of tryptophan to the effects of glycine on uric acid excretion .</segment>
<segment id="74" parent="1075" relname="span">Among the limitations in the current clinical study , the modest sample size</segment>
<segment id="75" parent="74" relname="elaboration">( n = 16 )</segment>
<segment id="76" parent="1074" relname="same_unit">might have reduced the statistical power</segment>
<segment id="77" parent="1076" relname="sequence">and increased the risk of type II error ,</segment>
<segment id="78" parent="1077" relname="joint">particularly regarding the statistical differences in multiple comparisons between the glycine and glycine + tryptophan groups .</segment>
<segment id="79" parent="1079" relname="span">Furthermore , the current study included only male subjects</segment>
<segment id="80" parent="79" relname="cause">because of the known effects of sex differences on serum uric acid levels .</segment>
<segment id="81" parent="1080" relname="span">Further studies are therefore needed ,</segment>
<segment id="82" parent="1082" relname="attribution">although our preliminary findings suggested</segment>
<segment id="83" parent="1082" relname="span">that there were no effective differences between males and females in response to glycine and tryptophan supplementation</segment>
<segment id="84" parent="83" relname="elaboration">( data not shown ) .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1004" relname="background"/>
<group id="1003" type="span" parent="1002" relname="span"/>
<group id="1004" type="multinuc" parent="1001" relname="span"/>
<group id="1005" type="span" parent="1004" relname="joint"/>
<group id="1006" type="multinuc" parent="1005" relname="span"/>
<group id="1007" type="span" parent="1006" relname="same_unit"/>
<group id="1008" type="multinuc" parent="1004" relname="joint"/>
<group id="1009" type="span" parent="1008" relname="contrast"/>
<group id="1010" type="multinuc" parent="1008" relname="contrast"/>
<group id="1011" type="span" parent="1010" relname="joint"/>
<group id="1014" type="span" parent="1010" relname="joint"/>
<group id="1015" type="span" parent="1014" relname="span"/>
<group id="1016" type="span" parent="1015" relname="span"/>
<group id="1017" type="span" parent="1016" relname="span"/>
<group id="1018" type="multinuc" parent="1016" relname="elaboration"/>
<group id="1019" type="span" parent="1018" relname="joint"/>
<group id="1020" type="span" parent="19" relname="elaboration"/>
<group id="1021" type="span" parent="20" relname="elaboration"/>
<group id="1022" type="multinuc" parent="1018" relname="joint"/>
<group id="1023" type="span" parent="1022" relname="joint"/>
<group id="1024" type="multinuc" parent="1022" relname="joint"/>
<group id="1025" type="span" parent="1024" relname="joint"/>
<group id="1026" type="multinuc" parent="1024" relname="joint"/>
<group id="1027" type="multinuc" parent="1026" relname="joint"/>
<group id="1028" type="multinuc" parent="1026" relname="joint"/>
<group id="1029" type="multinuc" parent="1028" relname="joint"/>
<group id="1030" type="multinuc" parent="1028" relname="joint"/>
<group id="1031" type="span" parent="1030" relname="joint"/>
<group id="1032" type="span" parent="1031" relname="span"/>
<group id="1033" type="multinuc" parent="1030" relname="joint"/>
<group id="1034" type="span" parent="1033" relname="joint"/>
<group id="1035" type="multinuc" parent="1036" relname="preparation"/>
<group id="1036" type="multinuc" parent="1034" relname="span"/>
<group id="1037" type="multinuc" parent="1036" relname="joint"/>
<group id="1038" type="multinuc" parent="1037" relname="joint"/>
<group id="1039" type="span" parent="1038" relname="same_unit"/>
<group id="1040" type="span" parent="1042" relname="concession"/>
<group id="1041" type="span" parent="39" relname="elaboration"/>
<group id="1042" type="span" parent="1039" relname="span"/>
<group id="1043" type="multinuc" parent="1037" relname="joint"/>
<group id="1044" type="multinuc" parent="1043" relname="joint"/>
<group id="1045" type="span" parent="1044" relname="same_unit"/>
<group id="1046" type="multinuc" parent="1044" relname="same_unit"/>
<group id="1047" type="span" parent="1046" relname="same_unit"/>
<group id="1048" type="multinuc" parent="1043" relname="joint"/>
<group id="1049" type="span" parent="1048" relname="joint"/>
<group id="1050" type="multinuc" parent="1048" relname="joint"/>
<group id="1051" type="span" parent="1050" relname="joint"/>
<group id="1052" type="multinuc" parent="1050" relname="joint"/>
<group id="1053" type="span" parent="1052" relname="joint"/>
<group id="1054" type="multinuc" parent="1052" relname="joint"/>
<group id="1055" type="span" parent="1054" relname="joint"/>
<group id="1056" type="multinuc" parent="1055" relname="span"/>
<group id="1057" type="span" parent="1056" relname="joint"/>
<group id="1058" type="multinuc" parent="1057" relname="span"/>
<group id="1059" type="span" parent="1058" relname="joint"/>
<group id="1060" type="span" parent="59" relname="elaboration"/>
<group id="1061" type="multinuc" parent="1058" relname="joint"/>
<group id="1062" type="span" parent="1061" relname="joint"/>
<group id="1063" type="multinuc" parent="1061" relname="joint"/>
<group id="1064" type="span" parent="1063" relname="joint"/>
<group id="1065" type="span" parent="64" relname="elaboration"/>
<group id="1066" type="multinuc" parent="1063" relname="joint"/>
<group id="1067" type="span" parent="1066" relname="sequence"/>
<group id="1068" type="multinuc" parent="1066" relname="sequence"/>
<group id="1069" type="span" parent="1068" relname="joint"/>
<group id="1070" type="multinuc" parent="1068" relname="joint"/>
<group id="1071" type="span" parent="1070" relname="joint"/>
<group id="1072" type="span" parent="71" relname="purpose"/>
<group id="1073" type="multinuc" parent="1070" relname="joint"/>
<group id="1074" type="multinuc" parent="1073" relname="joint"/>
<group id="1075" type="span" parent="1074" relname="same_unit"/>
<group id="1076" type="multinuc" parent="1073" relname="joint"/>
<group id="1077" type="multinuc" parent="1076" relname="sequence"/>
<group id="1078" type="multinuc" parent="1077" relname="joint"/>
<group id="1079" type="span" parent="1078" relname="joint"/>
<group id="1080" type="span" parent="1078" relname="joint"/>
<group id="1081" type="span" parent="81" relname="concession"/>
<group id="1082" type="span" parent="1081" relname="span"/>
	</body>
</rst>
